Changes of Tyrosine Phosphorylation in Liver and Kidney of Polycystic Ovarian Rats Induced by Letrozole

Cambios de Fosforilación de Tirosina en Hígado y Riñón de Ratas Ováricas Poliquísticas Inducidas por Letrozol

Arada Chaiyamoon¹; Sudtida Bunsueb¹ & Sitthichai Iamsaard¹,²


SUMMARY: Letrozole (Letro) is a drug commonly used for breast cancer treatment since it can decrease estrogen level. In experimental animal, the Letro has been used to induce the polycystic ovarian syndrome (PCOS) model. Tyrosine phosphorylation (TyrPho) is an essential process in various biological functions both normal and abnormal conditions especially reproduction. Although some side effects of Letro are reported, the alterations of TyrPho responsible for liver and kidney functions have never been demonstrated. In this study, the blood serum, liver, and kidney of control and PCOS rats induced with Letro (orally, 1 mg/ KgBW) for consecutive 21 days were used to determine the serum biochemical components and to investigate the TyrPho expression using western blot analysis. Histopathology of such tissues was observed by Masson’s trichrome staining. The results showed that Letro did not affect histological structures but significantly increased the serum levels of urea nitrogen, cholesterol, triglyceride, HDL, LDL, ALT, AST, and alkaline phosphatase. Additionally, the TyrPho protein expressions of 32 and 27 kDas in liver and of 55 and 43 kDas in kidney were increased while of a kidney 26 kDa was decreased as compared to those of control. In conclusion, this recent study indicated that the changes of TyrPho proteins in liver and kidney induced with Letro associated with their functions by alteration of serum biochemical levels.

KEY WORDS: Letrozole; Tyrosine phosphorylation; Liver; Kidney; Rats.

INTRODUCTION

Tyrosine phosphorylation (TyrPho) is a biological process which is adding of a phosphoryl group to tyrosine residual of protein structure. Consequently, the TyrPho proteins are important to control various cellular mechanisms especially in eukaryotes including cell proliferation, differentiation, and cell death (Hunter, 1987; Ullrich & Schlessinger, 1990; Hagar et al., 1997). It has been reported that the multiple intracellular signaling pathways in liver regeneration are regulated by tyrosine phosphorylation (Pagano et al., 2012). This process is also shown to involve in induction of kidney tumor (Narayan & Roy, 1992). Indeed, the expressions of TyrPho proteins were found in differentiation of both normal and carcinoma cells (Paul & Mukhopadhyay, 2004). In current researches especially in reproductive system, the TyrPho proteins have been localized in testis (Arun et al., 2016a), epididymis (Sawatpanich et al., 2018), and seminal vesicle (Tongpan et al., 2019) of rats. It was well known that those protein expressions are changed when animals are treated with chemicals or being diseases such as stress and diabetic mellitus. Moreover, the phosphorylation rates of tyrosine protein were demonstrated to be increased in apoptotic neural cell death (Chromy et al., 2000).

Letrozole (Letro) or Femara is a non-steroidal aromatase inhibitor clinically used to reduce estrogen level via steroidal synthesis inhibition for breast cancer treatment (He & Ma, 2016) and to delay cancer cell metastasis (Wang et al., 2016). The Letro was also used for gastric cancer treatment (El Hadi, 2011). As it has property like aromatase inhibitor, Letro commonly used to induce polycystic ovary syndrome (PCOS) in the animal model in study of its mechanism and prevention for PCOS infertile patients. Interestingly, it has been reported that an aromatase inhibitor letrozole is not superior to the clomiphene in patients with PCOS (Guang, 2018). Many women with PCOS are associated with an increased risk of metabolic syndrome, obesity, and type 2 diabetes (Torres et al., 2019). In previous study, the effects of aromatase inhibitor letrozole on tyrosine phosphorylated protein expression in liver and kidney have

¹ Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand.
² Research Institute for Human High Performance and Health Promotion (HHP & HP), Khon Kaen University, Khon Kaen, 40002, Thailand.
never been demonstrated. We therefore aimed to investigate the alterations of liver and renal function parameters and of their tissue TyrPho expressions in rats induced with Letro.

MATERIAL AND METHOD

Animals and experimental design: The Wistar female rats (180-200 g) were purchased from the Nomura Siam International Co., Ltd., Pathumwan, Bangkok, Thailand before transferring to the Animal Laboratory Unit, Faculty of Medicine, Khon Kaen University, Thailand. This experiment was approved by the Animal Ethics Committee of Faculty of Medicine, Research Affairs, Khon Kaen University (Record No. AEMDKKU 011/2019). After acclimatization for 7 days, the animals (n = 7, each group) were divided into 2 groups; control group orally received carboxymethyl cellulose solution (Union science trading, Thailand) and letrozole treated group was induced for PCOS by oral administration with letrozole (Femora®, Inhouse pharmacy, USA), 1 mg/KgBW for consecutive 21 days (Kafali et al., 2004).

Sample collection and histopathological study: After euthanasia and abdominal wall opening, both liver and kidney were collected and fixed in 10 % formalin diluted with PBS, pH 7.4 for 48 h. The fixed specimens were histologically processed by using automatic tissue processor at the Department of Pathology, Faculty of Medicine, Khon Kaen University. Subsequently, the infiltrated samples were embedded in paraffin and sectioned with 5-7 mm thickness. Then, the paraffin sections were stained with Masson trichrome (catalogue no. HT15, Sigma-Aldrich) to investigate the thickness of the collagen fibers and histological changes in liver and kidney tissues. All microphotographs were captured by using Nikon light ECLIPSE E200 microscope with a DKM1200 digital camera.

Serum collection and biochemical assays: Blood from all animals was collected from the left ventricle by cardiac puncture and centrifuged at 12000 rpm, 4 °C for 10 min to separate the serum from blood cells. The serum was sent to Clinical Chemistry Unit, Srinagarind Hospital, Faculty of Medicine, KKU, Thailand, for biochemical analyses of blood glucose level and liver and renal function parameters.

Table I. Comparisons of the serum biochemical parameters between control and letrozole-treated female rats.

<table>
<thead>
<tr>
<th>Serum biochemical parameters</th>
<th>Control</th>
<th>Letrozole</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood sugar (mg/dL)</td>
<td>198.94 ± 10.29</td>
<td>204.50 ± 1.19</td>
</tr>
<tr>
<td>Urea nitrogen (mg/dL)</td>
<td>19.10 ± 0.00</td>
<td>23.70 ± 0.08*</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.29 ± 0.00</td>
<td>0.27 ± 0.00*</td>
</tr>
<tr>
<td>Cholesterol (mg/dL)</td>
<td>49.40 ± 1.67</td>
<td>64.00 ± 0.00*</td>
</tr>
<tr>
<td>Triglyceride (mg/dL)</td>
<td>53.40 ± 1.67</td>
<td>67.00 ± 0.79*</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>36.05 ± 1.25</td>
<td>49.50 ± 0.40*</td>
</tr>
<tr>
<td>LDL (mg/dL)</td>
<td>5.35 ± 0.42</td>
<td>8.00 ± 0.00*</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>24.70 ± 0.84</td>
<td>35.50 ± 0.40*</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>70.75 ± 2.09</td>
<td>111.50 ± 1.19*</td>
</tr>
<tr>
<td>Alkaline phosphatase (U/L)</td>
<td>58.75 ± 2.09</td>
<td>124.00 ± 0.79*</td>
</tr>
</tbody>
</table>

*Statistically significant difference (P < 0.05) compared to control. Data are expressed as mean ± SD (N=5).

RESULTS

The results showed that all parameters of serum biochemistry except the blood sugar in the letrozole (Letro) treated animals were significantly different from those of control rats (P < 0.05) as shown in the Table I. It was found that the serum levels of urea nitrogen, cholesterol, triglyceride, HDL, LDL, ALT, AST, and alkaline phosphatase in Letro
group were significantly increased as compared to control (Table 1). However, only creatinine level was significantly decreased in Letro-treated animals.

In addition, it was demonstrated that the total protein profiles of liver lysates revealed by SDS-PAGE of control and Letro-treated groups were not obviously altered (Fig. 1, left panel). Interestingly, the intensities of 32 and 27 tyrosine phosphorylated proteins of liver tissue in Letro group were higher than those of control (Fig. 1, right panel).

Similar to SDS-PAGE results of the liver, no difference of the total protein profiles in kidney lysates between control and Letro-treated groups were found (Fig. 2, left panel). However, it was shown that the intensities of 55 and 43 tyrosine phosphorylated proteins of kidney tissue in Letro group were increased as compared to control (Fig. 1, right panel). However, a kidney tyrosine phosphorylated protein of 26 kDa showed more expression in Letro-treated group.

Figure 3 showed the histology of liver and kidney stained by Masson’s trichrome to observe the histopathology such as fibrotic tissue and cellular abnormality in letrozole treatment. As observed, no fibrosis and cellular damage in hepatic portal triad or in renal tubular and corpuscle were found in control and Letro-treated groups (Fig. 3).
DISCUSSION

Herein, our results have shown that the treatment of letrozole (Letro, 1 mg/ KgBW) for consecutive 21 days) affected the most biochemical functions of blood serum. Such alterations indicate abnormality of liver and kidney functions although their histological structures were not obviously changed, including no fibrosis appearance. In fact, a dose of Letro used in this study is a common dose applied for polycystic ovarian syndrome (PCOS) induction (Kar, 2013; Palomba, 2015; Pandey et al., 2016; Tanbo et al., 2018). Indeed, the animals induced with Letro in our study show significant increase of androgen (testosterone) level and predominant polycystic follicles revealed by histology (data not shown). Therefore, it is difficult to explain whether Letro or consequence of PCOS by elevated androgen could directly affect the liver and kidney functions. Possibly, the dysfunctions of such vital organs may be caused from direct Letro interaction or excess androgen levels. Letro is known to be an aromatase inhibitor exhibiting anti-estrogenic activity which used as endocrine therapy for patients with breast cancer. Although associations between metabolic and liver adverse effects of Letro from previous works are still conflicting, our results and other have demonstrated the increase of serum lipid profiles including cholesterol, triglyceride, HDL, and LDL, respectively (Hewitt et al., 2004; Moro et al., 2010). This drug seemed not to affect the metabolic and lipid profiles in ovariectomized rats (Butus et al., 2015) but it increased hepatic function parameters (Aydin et al., 2011). In contrast to our results, the long period of Letro treatment has been shown to have the lipid accumulation and hepatic steatosis in the liver (Hewitt et al.; Moro et al.). In the PCOS rats, we have demonstrated for the first time that Letro significantly increased the renal function parameters but did not change the uriniferous tubules. As previously reviewed, the gonadal dysfunctions are related to renal failure and liver diseases (Karagiannis & Harsoulis, 2005). Therefore, the increase of function parameters of liver and kidney induced by Letro might be caused from both aromatase inhibition and estrogenic impairment.

Tyrosine phosphorylation (TyrPho) is an essential process involved in many physiological mechanisms such as cellular signaling pathways. Particularly, the alterations of TyrPho proteins in reproductive system have been shown to be sensitive to cancer drug treatments (Iamsaard et al., 2014; Iamsaard et al., 2017; Sukhorum & Iamsaard, 2017; Iamsaard et al., 2018; Sawatpanich et al.; Chaichun et al., 2019; Tongpan et al.), diabetic mellitus (Yannasithinon & Iamsaard, 2009; Sampannang et al., 2018, 2019), and stress conditions (Arun et al., 2016a,b, 2018). Currently, it has been reported that the decreased expression of a TyrPho protein in kidney induced by valproic acid, an antiepileptic drug, is associated with the increased malondialdehyde levels and renal vasodilation (Maneenin et al., 2019). Demonstrated for the first time, the expressions of many TyrPho proteins in liver and kidney of PCOS rats induced by Letro in this study was changed. It is possible that those proteins may play the important roles in regulation of functional factor parameters produced from liver and kidney. In conclusion, not only Letro can induce PCOS in rat model, it also alters the TyrPho protein in liver and kidney, resulting in increase of biochemical function parameters in blood serum.

REFERENCES


